Daniel Wynn

Medicine · Health Sciences

31h-index5.6kcitations65works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Sclerosis Research Studies(53), Peripheral Neuropathies and Disorders(13), Polyomavirus and related diseases(10), Autoimmune and Inflammatory Disorders Research(9), Immunotherapy and Immune Responses(7)

Publications64 total

Five Years of Ublituximab in Relapsing Multiple Sclerosis: Additional Results from Open-label Extension of ULTIMATE I and II Studies (P11-1.006)
Neurology·2025
No Association Between Decreases in Serum Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) and Serious Infections (SI) with Long-term Ublituximab (UBL) Treatment in Patients with Relapsing Multiple Sclerosis (RMS) (P7-1.017)
Neurology·2025
Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis
Frontiers in Neurology·2024· 5 citedOpen Access
Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives
Neurology and Therapy·2024· 7 citedOpen Access
Ublituximab Efficacy in Treatment-Naive Participants With Relapsing Multiple Sclerosis in the Phase 3 ULTIMATE I and II Studies (P6-3.015)
Neurology·2023· 3 cited
Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis
Multiple Sclerosis and Related Disorders·2022· 3 cited
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis
New England Journal of Medicine·2022· 170 cited
Disability Improvements With Ublituximab in Relapsing Multiple Sclerosis (RMS): Expanded Disability Status Scale (EDSS), 9-Hole Peg Test (9-HPT), and Timed 25-Foot Walk (T25FW) Evaluations From the Phase 3 ULTIMATE I and II Studies (P5-4.009)
Neurology·2022· 2 cited
Infusion-Related Reactions (IRRs) With Ublituximab in Patients With Relapsing Multiple Sclerosis (RMS): Post Hoc Analyses From the Phase 3 ULTIMATE I and II Studies (P6-4.010)
Neurology·2022· 2 cited
Relapse Rate and Time to First Relapse Were Improved With Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I and ULTIMATE II Studies in Patients With Relapsing Multiple Sclerosis (RMS) (P1-1.Virtual)
Neurology·2022· 1 cited
Ublituximab Treatment Is Associated With a Significant Proportion of Patients Achieving No Evidence of Disease Activity (NEDA): Results From the Ultimate I and Ultimate II Phase 3 Studies of Ublituximab vs Teriflunomide in Relapsing Multiple Sclerosis (RMS) (P6-4.005)
Neurology·2022
Results from a multicenter, randomized, double‐blind, placebo‐controlled study of repository corticotropin injection for multiple sclerosis relapse that did not adequately respond to corticosteroids
CNS Neuroscience & Therapeutics·2022· 8 citedOpen Access
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial
The Lancet Neurology·2021· 178 citedOpen Access
Efficacy and safety of ublituximab versus teriflunomide in relapsing multiple sclerosis: Results of the Phase 3 ULTIMATE I and II trials (4494)
Neurology·2021· 3 cited
Efficacy and Safety of Tolebrutinib in Patients With Highly Active Relapsing MS: Subgroup Analysis of the Phase 2b Study (2260)
Neurology·2021· 7 cited
Monomethyl fumarate has better gastrointestinal tolerability profile compared with dimethyl fumarate
Multiple Sclerosis and Related Disorders·2020· 27 citedOpen Access
Baseline Demographics and Disease Characteristics from the ULTIMATE Phase III Trials Evaluating Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Multiple Sclerosis (4845)
Neurology·2020
Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis
Multiple Sclerosis Journal·2019· 33 citedOpen Access
Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use
Multiple Sclerosis International·2019· 24 citedOpen Access
Real-World Fingolimod First-Dose Effects in Patients with Pre-Existing Hypertension, Pre-Existing Cardiac Conditions and in Those Receiving Selective Serotonin-Reuptake Inhibitors (P2.065)
Neurology·2016
page 1 of 4Next →

Frequent Co-authors

Sibyl Wray(9), Edward Fox(9), Derrick Robertson(8), Peter A. Calabresi(7), Christian Confavreux(7), Steven Galetta(7), Fred Lublin(7), Frances Lynn(7), Michael Panzara(7), Hans‐Peter Hartung(7), Krzysztof Selmaj(7), Eva Havrdová(6), DeRen Huang(6), Lawrence Steinman(6), Enrique Álvarez(6), Peiqing Qian(6), Koby Mok(6), Richard A. Rudick(5), Bianca Weinstock‐Guttman(5), Gavin Giovannoni(5)